TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8778603

Group type: EXPERIMENTAL
Intervention: sodium benzoate, alone or in combination with sodium phenylacetate or sodium phenylbutyrate, or sodium phenylbutyrate alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: sodium phenylacetate or sodium phenylbutyrate treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: not specified
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: drugs that activate new pathways of waste‐nitrogen excretion
Number of subjects: 32
Study: 1405170

Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) group; intravesical instillation with 50 mg of ADM dissolved in 100 ml physiological saline.
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) group; intravesical instillation with 30 mg of MMC dissolved in 100 ml of physiological saline.
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group; transurethral resection or transurethral coagulation only.
Number of subjects: 144
Study: 2409845

Group type: EXPERIMENTAL
Intervention: 5% albumin (group A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (group H)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (group C)
Number of subjects: 15
Study: 30919040

Group type: EXPERIMENTAL
Intervention: Parallel antenna placement (group A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Crossed antenna placement (group B)
Number of subjects: 71
Study: 30595274

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (CART) 5 times/week for 4 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional treatment without any supervised exercise intervention
Number of subjects: 28
Study: 27618080

Group type: EXPERIMENTAL
Intervention: Intensive nutrition education
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual nutrition education (Control)
Number of subjects: 196
Study: 24667905

Group type: EXPERIMENTAL
Intervention: Intensive cognitive training for 10 days over 2 weeks with 4 to 5 hours of training each day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intensive cognitive training
Number of subjects: 21
Study: 22323895

Group type: EXPERIMENTAL
Intervention: Niacin extended-release/simvastatin (NER/S) 1000/40 mg/day for 4 weeks followed by 2000/40 mg/day for 8 weeks
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Niacin extended-release/simvastatin (NER/S)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day for 12 weeks
Number of subjects: 137
Study: 19804455

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine for 4 days followed by gemtuzumab ozogamicin on day 5 (Arm A)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine for 4 days combined with liposomal daunorubicin for 3 days (Arm B)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cytarabine given for 5 days combined with cyclophosphamide for 3 days and topotecan by continuous infusion for 5 days (Arm C)
Number of subjects: 82
Study: 17561795

Group type: EXPERIMENTAL
Intervention: Once-daily glargine (GL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Twice-daily 70/30 aspart premix
Number of subjects: 30
Study: 16082602

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy
Number of subjects: 2741

Group type: EXPERIMENTAL
Intervention: Triple end point (all-cause death, recurrent myocardial infarction, recurrent angina)
Number of subjects: 2741

Group type: COMPARATOR
Intervention: Not receiving reperfusion therapy
Number of subjects: 2741

Group type: COMPARATOR
Intervention: Death
Number of subjects: 2741
Study: 11990874

Group type: EXPERIMENTAL
Intervention: MS‐ET (exercise training)
Number of subjects: 26

Group type: COMPARATOR
Intervention: MS‐NI (nontraining)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 26

Group type: COMPARATOR
Intervention: All groups (MS‐ET, MS‐NI, Control)
Number of subjects: 26
Study: 10456206

Group type: EXPERIMENTAL
Intervention: Insulin tolerance test in the morning (0830 h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Insulin tolerance test in the evening (2030 h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fasting NEFA levels in the morning
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fasting NEFA levels in the evening
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: NEFA response to insulin in the morning
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: NEFA response to insulin in the evening
Number of subjects: 9
Study: 8642805

Group type: EXPERIMENTAL
Intervention: rilmenidine (1‐2 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: atenolol (50‐100 mg/day)
Number of subjects: 12
Study: 2144797

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infusion (50 ng/kg/min)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Converting enzyme inhibitor (CEI) enalapril (20 mg p.o. for 5 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control conditions (placebo)
Number of subjects: 13
Study: 7004678

Group type: EXPERIMENTAL
Intervention: Tienilic acid
Number of subjects: 38

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 29589410

Group type: EXPERIMENTAL
Intervention: Multistation exercise program (2 times/week for 6 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (continued regular training routines)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 28261426

Group type: EXPERIMENTAL
Intervention: QuikClot Combat Gauze (QCG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard gauze
Number of subjects: 60
Study: 25927452

Group type: EXPERIMENTAL
Intervention: Culturally tailored stroke education films (one in English and one in Spanish)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 250
Study: 23376868

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21047568

Group type: EXPERIMENTAL
Intervention: Fluvastatin (3 times 40 mg at 0 hr, 24 hr, and 48 hr)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg at 0 hr) plus placebo (24 hr and 48 hr)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (0 hr, 24 hr and 48 hr)
Number of subjects: 60
Study: 19274640

Group type: EXPERIMENTAL
Intervention: Memantine treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 17315136

Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: 1-h post-load glucose
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: 2-h post-load glucose
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Fasting glucose, 1-h post-load glucose, 2-h post-load glucose
Number of subjects: 672
Study: 14722173

Group type: EXPERIMENTAL
Intervention: Articaine 2%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine/lidocaine
Number of subjects: 0
Study: 12408169

Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 54
Study: 9587121

Group type: EXPERIMENTAL
Intervention: Staging system based on risk score
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Staging system based on calculated volume of prostate carcinoma and PSA (cVCa-PSA)
Number of subjects: 1441
Study: 7843867

Group type: EXPERIMENTAL
Intervention: Hatha-Yoga exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (reading in a comfortable position)
Number of subjects: 0
Study: 2974934

Group type: EXPERIMENTAL
Intervention: nicardipine + fenoterol + ipratropium bromide
Number of subjects: 11

Group type: COMPARATOR
Intervention: nicardipine + fenoterol
Number of subjects: 11
Study: 29962176

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum TWK10 supplementation for 6 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27521177

Group type: EXPERIMENTAL
Intervention: Cox maze IV procedure (CMP‐IV), n = 60
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Modified Cox maze IV procedure (MCMP‐IV), n = 60
Number of subjects: 120

Group type: COMPARATOR
Intervention: Modified Cox maze IV procedure (MCMP‐IV)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cox maze IV procedure (CMP‐IV)
Number of subjects: 120
Study: 25791056

Group type: EXPERIMENTAL
Intervention: Conductive thermal mattress (CTM)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 160
Study: 23357887

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral skills program focused on decision making and substance use, duration not specified.
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral skills program
Number of subjects: 243
Study: 20010551

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 18328724

Group type: EXPERIMENTAL
Intervention: Off-pump (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: On-pump (group B)
Number of subjects: 20
Study: 15848261

Group type: COMPARATOR
Intervention: Conventional physical therapy (control group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Therapy combined with standing balance training by biofeedback (BPM Monitor)
Number of subjects: 26
Study: 12585949

Group type: EXPERIMENTAL
Intervention: Carvedilol (3.125 mg twice daily, uptitrated to 25 mg twice daily)
Number of subjects: 2289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2289
Study: 10565463

Group type: EXPERIMENTAL
Intervention: CSF glycine levels in newborns with moderate HIE (19.1 micromol/l)
Number of subjects: 48

Group type: COMPARATOR
Intervention: CSF glycine levels in control group (12.08 micromol/l)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CSF glycine levels in newborns without HIE (12.49 micromol/l)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CSF glycine levels in newborns with mild HIE (12.14 micromol/l)
Number of subjects: 48
Study: 8984864

Group type: EXPERIMENTAL
Intervention: morphine 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: buprenorphine 30 micrograms
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 0
Study: 2015476

Group type: COMPARATOR
Intervention: Varicose veins without complications
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Varicose veins with lipodermatosclerosis
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Varicose veins with a history of ulceration
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Raising venous pressure for 30 min
Number of subjects: 14
Study: 500575

Group type: EXPERIMENTAL
Intervention: Nylidrin HCL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31918168

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 58

Group type: COMPARATOR
Intervention: Thinking-as-usual control
Number of subjects: 58
Study: 31010345

Group type: EXPERIMENTAL
Intervention: Intrauterine misoprostol 800 µg with oxytocin (group A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Oxytocin alone (group B)
Number of subjects: 160
Study: 28449402

Group type: EXPERIMENTAL
Intervention: lixisenatide 20 µg
Number of subjects: 35

Group type: COMPARATOR
Intervention: insulin-glulisine (iGlu)
Number of subjects: 35
Study: 26030788

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 400 IU/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 800 IU/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Free vitamin D levels at birth
Number of subjects: 32
Study: 23870608

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of ASA 100 mg and clopidogrel 75 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Free combination of ASA and clopidogrel
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both formulations (fixed-dose and free combination)
Number of subjects: 64
Study: 21898310

Group type: EXPERIMENTAL
Intervention: Preventive intervention programme (watchful waiting, bibliotherapy, problem-solving treatment, re-referral to primary care)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 170
Study: 19109835

Group type: EXPERIMENTAL
Intervention: CUSA with radiofrequency coagulator (TissueLink)
Number of subjects: 24

Group type: COMPARATOR
Intervention: CUSA with bipolar cautery
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 17898401

Group type: EXPERIMENTAL
Intervention: Gabapentin plus dexamethasone (800 mg gabapentin and 8 mg dexamethasone IV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gabapentin (800 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dexamethasone (8 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 80
Study: 14978608

Group type: EXPERIMENTAL
Intervention: Intervention group (protocol applied)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 298
Study: 11533837

Group type: EXPERIMENTAL
Intervention: 8 mg/kg per day of oral iron
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 16 mg/kg per day of oral iron
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of both doses (8 mg/kg vs 16 mg/kg)
Number of subjects: 30
Study: 9934543

Group type: EXPERIMENTAL
Intervention: Cefotaxime 50 mg/kg twice-daily (n = 130)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Cefotaxime 33.3 mg/kg three-times-daily (n = 128)
Number of subjects: 258
Study: 8109809

Group type: EXPERIMENTAL
Intervention: Salbutamol delivered from a metered dose inhaler (MDI)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Salbutamol delivered from a novel multiple dose powder inhaler (MDPI) Easyhaler
Number of subjects: 20

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MDPI actuated during inhalation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MDPI released before inhalation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MDI and MDPI
Number of subjects: 20
Study: 3287996

Group type: EXPERIMENTAL
Intervention: Budesonide 25 micrograms q.i.d.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Budesonide 100 micrograms q.i.d.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms q.i.d.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31037343

Group type: EXPERIMENTAL
Intervention: P11-4
Number of subjects: 37

Group type: COMPARATOR
Intervention: Fluoride varnish
Number of subjects: 37
Study: 29718314

Group type: COMPARATOR
Intervention: No radiotherapy (no-RT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 0
Study: 28296582

Group type: EXPERIMENTAL
Intervention: Hypofractionated RT (60 Gy in 20 fractions over 4 weeks)
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Conventional RT (78 Gy in 39 fractions over 8 weeks)
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Hypofractionated RT
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Conventional RT
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 1206
Study: 25946929

Group type: EXPERIMENTAL
Intervention: 100,000 IU of oral vitamin D per month for 6 months
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 22770481

Group type: EXPERIMENTAL
Intervention: Halogen bleaching (38% hydrogen peroxide, 8 minutes)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser bleaching (38% hydrogen peroxide, 30 seconds)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chemical activation only (38% hydrogen peroxide)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Halogen bleaching
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser and chemical activation
Number of subjects: 60
Study: 21467234

Group type: EXPERIMENTAL
Intervention: rs6497287 genetic variant on 15q13
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: rs3774315 genetic variant on 3q26
Number of subjects: 202
Study: 18809783

Group type: EXPERIMENTAL
Intervention: Plasma arc light (Ortho LITE, 3M Unitek)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional tungsten-quartz halogen curing light (Visilux 2, 3M Unitek)
Number of subjects: 43
Study: 17919621

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 90
Study: 15201943

Group type: EXPERIMENTAL
Intervention: Anakinra (interleukin-1 receptor antagonist)
Number of subjects: 2932

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2932
Study: 11535498

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative SCT (fludarabine/cyclophosphamide conditioning)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Myeloablative SCT (cyclophosphamide/high-dose total body irradiation)
Number of subjects: 14
Study: 9573752

Group type: EXPERIMENTAL
Intervention: Gonadotropin‐Releasing Hormone analogue (two injections monthly)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 60
Study: 7530724

Group type: EXPERIMENTAL
Intervention: Subdermal levonorgestrel (Norplant) users
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normally cycling women
Number of subjects: 0
Study: 2899773

Group type: EXPERIMENTAL
Intervention: Sodium fluoride 25 mg twice daily plus elemental calcium 1 g daily and a vitamin D2 supplement
Number of subjects: 257

Group type: COMPARATOR
Intervention: Alternative therapies usually prescribed in France
Number of subjects: 257
Study: 31017912

Group type: EXPERIMENTAL
Intervention: 10-item USDA Adult Food Security Survey Module (FSSM) with the 2-item food sufficiency screener
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: 2-item food sufficiency screener
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: 10-item FSSM
Number of subjects: 462
Study: 28228452

Group type: EXPERIMENTAL
Intervention: Patient decision aid
Number of subjects: 155

Group type: COMPARATOR
Intervention: Standard preoperative care
Number of subjects: 155
Study: 26729437

Group type: EXPERIMENTAL
Intervention: Exemestane plus triptorelin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Tamoxifen plus triptorelin
Number of subjects: 116
Study: 24814037

Group type: EXPERIMENTAL
Intervention: 3g red ginseng daily for 12 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 22705480

Group type: EXPERIMENTAL
Intervention: Sleep group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sleep deprivation group
Number of subjects: 34
Study: 19995506

Group type: EXPERIMENTAL
Intervention: Group A: Fissurit sealants applied using a single bottle adhesive system (One-step prior to sealant application)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Group B: Sealants applied using the conventional etch and seal technique
Number of subjects: 54
Study: 17322147

Group type: EXPERIMENTAL
Intervention: Controlled-release oxybutynin (15 mg once daily for 5 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Immediate-release oxybutynin (5 mg every 8 hours for 5 days)
Number of subjects: 18
Study: 15660119

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) increase of 10 mmHg
Number of subjects: 9338

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP)
Number of subjects: 9338
Study: 11986206

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (300 to 1000 mg per day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard cytarabine-based therapy
Number of subjects: 75
Study: 9719109

Group type: EXPERIMENTAL
Intervention: External radiation therapy plus temporary stereotactic iodine-125 implants delivering a minimum peripheral tumor dose of 60 Gy
Number of subjects: 140

Group type: COMPARATOR
Intervention: External radiation therapy only delivering 50 Gray (Gy) in 25 fractions over 5 weeks
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Randomization to the implant arm
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Chemotherapy or reoperation at recurrence
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: KPS > or =90
Number of subjects: 140
Study: 8083913

Group type: EXPERIMENTAL
Intervention: Sequential gradient pneumatic leg compression (SCD)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin (H)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 400
Study: 2689399

Group type: COMPARATOR
Intervention: Standard photon radiotherapy (60 and 70 Gy)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Radiation therapy and chemotherapy (60 Gy + BCNU and 60 Gy + MeCCNU + DTIC)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Photon irradiation plus neutron boost
Number of subjects: 163
Study: 30120605

Group type: EXPERIMENTAL
Intervention: High-viscosity glass ionomer (EQUIA Fil, GC)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Composite resin (G‐aenial, GC)
Number of subjects: 134
Study: 28317458

Group type: EXPERIMENTAL
Intervention: iFR-guided coronary revascularization
Number of subjects: 2492

Group type: COMPARATOR
Intervention: FFR-guided coronary revascularization
Number of subjects: 2492
Study: 26183105

Group type: EXPERIMENTAL
Intervention: PAC group (pantoprazole, amoxicillin, clarithromycin for 14 days)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PAM group (pantoprazole, amoxicillin, metronidazole for 14 days)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Bismuth-containing group (pantoprazole, bismuth subsalicylate, tetracycline, metronidazole for 14 days)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Sequential group (pantoprazole and amoxicillin for 5 days, followed by pantoprazole, tetracycline, and metronidazole for the next 5 days)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Concomitant group (pantoprazole, amoxicillin, tetracycline, and metronidazole for 10 days)
Number of subjects: 5
Study: 23542218

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT-I) administered 3 to 9 months poststroke
Number of subjects: 222

Group type: COMPARATOR
Intervention: Constraint-Induced Movement Therapy (CIMT-D) administered 15 to 21 months poststroke
Number of subjects: 222